Navigation Links
Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
Date:1/17/2008

MOUNTAIN VIEW, Calif., Jan. 17 /PRNewswire/ -- Cardiva Medical, Inc., a privately held medical device company and developer of the Boomerang Catalyst(TM) System is pleased to announce the addition of two officers to their management team. Malcolm Farnsworth joins Cardiva as Vice President of Finance and Chief Financial Officer. Tara Zerby joins Cardiva as Vice President of Business Development and Marketing.

"We are very excited to have Malcolm and Tara join Cardiva during this exciting stage in the company," says Augustine Lien, Chairman and CEO. "Their expertise in the medical device industry will be beneficial in the growth of our company."

Malcolm Farnsworth joined Cardiva in January 2008. Previously, Mr. Farnsworth served as Executive Vice President and Chief Financial Officer at POINT Biomedical Corporation, a specialty pharmaceutical company developing pharmaceutical imaging agents to detect coronary artery disease. Prior to that, he served as Vice President of Finance and Chief Financial Officer at Gynecare, Inc., a medical device company, that was acquired by Johnson & Johnson after its IPO in 1996. Before that he served as Vice President of Finance and Chief Financial Officer at Origin Medsystems, a minimally invasive surgical device company that was acquired by Eli Lilly and merged into Guidant. Mr. Farnsworth holds an M.B.A. degree from the Haas School, University of California at Berkeley and a B.S. degree in Business and Economics from Lehigh University.

Tara L. Zerby joined Cardiva in November 2007. Ms. Zerby brings with her over 25 years of experience in sales, marketing and management in the medical device industry. Prior to joining Cardiva, she served as Vice President and General Manager of RTI-Cardiovascular, formerly the Alabama Tissue Center. Ms. Zerby operated her own consulting firm, assisting start-up medical device companies. She was also the executive Director of Marketing and Clinical Applications for Stereotaxis, Inc., Business Unit Director, Surgical Systems and Director of Global Sales for Cryocath Technologies. Ms. Zerby holds an M.B.A. from University of Wisconsin, an M.A. from Georgia State and a B.A. from Wake Forest.

About Cardiva Medical, Inc.

Founded in July 2002, and headquartered in Mountain View, Calif., Cardiva Medical, Inc. is a privately held medical company focused on developing and commercializing vascular access site management and closure devices with unsurpassed safety and ease-of-use. Cardiva's first product, the Boomerang Wire System, was approved in EU countries and in the US in 2004. Cardiva's second-generation product, the Boomerang Catalyst System, was approved in March 2007 and launched in July 2007. The enhanced Boomerang Catalyst, trade named as "Boomerang Catalyst II System" received 510(K) clearance in September 2007 and launched in January 2008. Cardiva was selected by Frost & Sullivan as the recipient of the 2006 Frost & Sullivan Award for Entrepreneurial Company in the U.S. angioplasty and vascular closure devices market. For additional information about Cardiva Medical, Inc. see our website at http://www.cardivamedical.com.

Cardiva, Boomerang and Boomerang Catalyst System are trademarks/registered trademarks of Cardiva Medical, Inc.

Media Contact:

Glenn Foy, President

Cardiva Medical, Inc.

Phone: 650.964.8900, x 215

Fax: 650.964.8911

glenn_foy@cardivamedical.com


'/>"/>
SOURCE Cardiva Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
4. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
5. Medical, Behavioral Woes Can Drive Dogs to Bite
6. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
7. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
8. Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
11. WorldHeart Appoints David Pellone Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology: